How has been the historical performance of Trident Texofab?

Answer:The historical performance of Trident Texofab shows a steady increase in net sales and total operating income over the years, with net sales reaching 122.06 Cr in Mar'25, up from 99.48 Cr in Mar'24 and 96.36 Cr in Mar'23. The total expenditure also rose to 116.58 Cr in Mar'25, compared to 93.33 Cr in Mar'24, leading to an operating profit of 5.48 Cr in Mar'25, slightly down from 6.15 Cr in the previous year. Profit before tax improved to 2.58 Cr in Mar'25 from 1.17 Cr in Mar'24, while profit after tax increased to 2.51 Cr from 1.08 Cr. The company's equity capital grew to 13.56 Cr in Mar'25, and reserves surged to 33.68 Cr, indicating a strong financial position. However, total debt decreased to 26.50 Cr from 36.96 Cr, reflecting improved financial health. The cash flow from operating activities was negative at -13.00 Cr in Mar'25, but financing activities provided a significant inflow of 36.00 Cr.

Breakdown:
Trident Texofab's financial performance has shown a positive trend in net sales, which increased from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25. Total operating income followed a similar trajectory, reaching 122.06 Cr in Mar'25. Despite a rise in total expenditure to 116.58 Cr, the company managed to maintain an operating profit of 5.48 Cr. Profit before tax saw an increase to 2.58 Cr, while profit after tax rose to 2.51 Cr, indicating effective cost management and growth in profitability. The equity capital and reserves have significantly increased, reflecting a stronger balance sheet. Total liabilities rose to 100.58 Cr, but total debt decreased, showcasing improved leverage. Cash flow from operating activities was negative, but the financing activities generated a substantial inflow, contributing to a closing cash balance of 3.00 Cr in Mar'25.